重症急性呼吸器症候群(SARS)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0855
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:78
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2020, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 7 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Severe Acute Respiratory Syndrome (SARS) – Overview
Severe Acute Respiratory Syndrome (SARS) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Severe Acute Respiratory Syndrome (SARS) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Severe Acute Respiratory Syndrome (SARS) – Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Fab’entech SA
GeneCure LLC
Gilead Sciences Inc
Global BioLife Inc Ltd
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Sagimet Biosciences
Sirnaomics Inc
Suzhou Ribo Life Sciences Co Ltd
Severe Acute Respiratory Syndrome (SARS) – Drug Profiles
Antisense RNAi Oligonucleotide for Severe Acute Respiratory Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides for Severe Acute Respiratory Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATR-006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Cathepsin L for Coronaviridae Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FDX-000 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ML-188 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for SARS Virus Infections – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remdesivir – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SARS (virus like particle) vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
severe acute respiratory syndrome vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
severe acute respiratory syndrome vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Coronavirus E Protein for Severe Acute Respiratory Syndrome – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SSYA-10001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVB-3567 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Severe Acute Respiratory Syndrome (SARS) – Dormant Projects
Severe Acute Respiratory Syndrome (SARS) – Product Development Milestones
Featured News & Press Releases
Feb 04, 2020: Gilead’s remdesivir to enter trials for coronavirus treatment
Aug 04, 2014: Hemispherx’s Two Drugs, Ampligen and Alferon Ranked Highly in Sensitivity Testing Against MERS/SARS Coronaviruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by AIM ImmunoTech Inc, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Atriva Therapeutics GmbH, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Autoimmune Technologies LLC, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Biotron Ltd, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by CEL-SCI Corp, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Fab’entech SA, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by GeneCure LLC, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Gilead Sciences Inc, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Global BioLife Inc Ltd, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Novavax Inc, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Oncovir Inc, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Phelix Therapeutics LLC, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sagimet Biosciences, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Sirnaomics Inc, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Pipeline by Suzhou Ribo Life Sciences Co Ltd, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H1 2020
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects, H1 2020 (Contd..1), H1 2020

【掲載企業】

AIM ImmunoTech Inc
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Fab’entech SA
GeneCure LLC
Gilead Sciences Inc
Global BioLife Inc Ltd
Novavax Inc
Oncovir Inc
Phelix Therapeutics LLC
Sagimet Biosciences
Sirnaomics Inc
Suzhou Ribo Life Sciences Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[重症急性呼吸器症候群(SARS)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆